Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best performing Dow ...

On the other hand, sales of Repatha, the flagship of Amgen's cardiovascular franchise, reached $606 million, an increase of 45.3% compared to the fourth quarter of 2023. In this article ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...

Repatha sales beat the Zacks Consensus Estimate of $555.0 million and our model estimate of $542.9 million. While 2024 sales were impacted by price erosion, in 2025, Amgen expects less price ...